Various inhibitors of histone deacetylase (HDAC) activity can sensitize drug resistant cancer cells to chemotherapeutic agents. However, the mechanisms underlying such effects of distinct HDAC inhibitors (HDACi) remain poorly understood. Here we show that both the HDACi trichostatin A and valproic acid induced a sensitization of multidrug-resistant cancer cells to the topoisomerase II inhibitor etoposide/VP16. This effect was associated with increased acetylation of certain lysines on histones H3 and H4, including lysine 16 on histone H4 (H4K16). Overexpression of the histone acetyltransferase hMOF, known to target H4K16, was sufficient to mimic HDACi treatment on sensitization and H4K16 acetylation, and importantly, small-interfering RNA (siRNA)-mediated knockdown of hMOF abolished the HDACi-mediated sensitizing effects as well as the increase in H4K16 acetylation. Conversely, siRNA-mediated knockdown of the H4K16 deacetylase SIRT1 mimicked HDACi treatment whereas overexpression of SIRT1 abolished H4K16 acetylation and significantly reduced the sensitizing effects of HDACi. Interestingly, the effects of hMOF on H4K16 acetylation and sensitization to the topoisomerase II inhibitor could be directly counteracted by exogenous expression of increasing amounts of SIRT1 and vice versa. Our study results suggest that hMOF and SIRT1 activities are critical parameters in HDACi-mediated sensitization of multidrug-resistant cancer cells to topoisomerase II inhibitor and increased H4K16 acetylation.
Introduction
Histone lysine modifications are directly influencing activation and repression of transcription, and are also essential for proper elongation and higher-order chromatin structure depending on which residue is modified and at what position in the gene such residue is located (Schneider and Grosschedl, 2007) . Histone deacetylases (HDACs) and histone acetyltransferases (HAT) control the acetylation state of lysine residues, including those situated in the N-terminal 'tails' of the histones. In addition, posttranslational modification by acetylation/ deacetylation by these classes of enzymes of non-histone proteins, including transcription factors and co-regulators, has emerged as a regulatory mechanism controlling the function, activity and stability of these proteins (Hermanson et al., 2002; Glozak et al., 2005; Liu et al., 2009) . In promoters, the acetylation of such histone lysines, including lysine 9 on histone H3 (H3K9), is believed to directly influence the recruitment of activator and repressor complexes to the chromatin (Schneider and Grosschedl, 2007) . In addition, modifications of H3K9 and lysine 16 on histone H4 (H4K16) in exons are associated with elongation control, and the acetylation state of lysine residues thus regulates both the local chromatin dynamics and the higher-order chromatin structure (Shogren-Knaak et al., 2006) . HDAC inhibitors (HDACi) constitute a relatively new class of chemotherapeutic drugs. These inhibitors exert multiple antineoplastic effects both in vitro and in vivo. In a short period of time, HDACi have shown promising results in preclinical and clinical trials with low toxicity in certain solid tumors and hematological malignancies (Bolden et al., 2006) . In addition to their intrinsic anticancer properties, HDACi can modulate cellular responses to other cytotoxic modalities including ionizing and ultraviolet radiation and chemotherapeutic drugs (Karagiannis and El-Osta, 2006; Hajji et al., 2008) . Many mechanisms have been proposed to explain the action of various HDACi, yet little is understood regarding how distinct HDACi can yield similar cellular effects seemingly regardless of structure and specificity. Interestingly, loss of total H4K16 acetylation has been suggested to represent one common hallmark of cancer cells (Fraga et al., 2005) . The H4K16 residue is of particular interest as acetylation of this lysine residue is sufficient to induce reorganization of higher-order chromatin structure (Shogren-Knaak et al., 2006) .
The aim of this study was to investigate putative common mechanisms underlying sensitization by different HDACi of drug-resistant cancer cells to the topoisomerase II inhibitor etoposide/VP16. Our study results suggest that HDACi-induced sensitization was associated with increased histone acetylation, including that of H4K16, and that the HAT hMOF and the HDAC SIRT1 influenced not only H4K16 acetylation levels but also the HDACi-induced sensitization of the drug-resistant cells to etoposide.
Results
HDAC inhibitors reverse NSCLC cell resistance to VP16-induced DNA damage and cell death Non-small-cell lung carcinoma (NSCLC) H157 cells were initially selected for this study based on their known resistance to g-ionizing radiation as well as etoposide/VP16, a well-characterized and specific topoisomerase II inhibitor used clinically in chemotherapy and known to be lethal to normal cell types (Hajji et al., 2008) . We first treated cells with structurally and functionally divergent inhibitors (HDACi) valproic acid (VPA, 1 mM) or trichostatin A (TSA, 20 ng/ml; 66 nM) alone or in combination with VP16 (5 mM). Treatment with either TSA or VPA alone did not induce any apparent increase in cell death, whereas both HDACi sensitized H157 cells to VP16-induced cell death (Figures 1a and b) . We have recently shown that exposure to TSA but not VPA induces decreased BclxL expression and thereby initiation of a caspase-mediated AIF-dependent apoptotic cell death (Hajji et al., 2008) . Whereas TSA promoted VP16-induced apoptotic cell death, VPA/VP16 co-treatment induced nuclear morphology resembling mitotic catastrophe (Figure 1b) , an event associated with block in mitosis, mitotic spindle disorganization, failed chromosome segregation and formation of multinucleated cells (Castedo et al., 2004) . Later on these cells died by necrosis-like lysis (Vakifahmetoglu et al., 2008) . The promoting effect of TSA and VPA treatment on VP16-induced cell death was further investigated and confirmed by clonogenic assay at 10 days (Figures 2a-c) . Colonies from VPAonly treated cells presented an apparent increase in size, indicating that VPA treatment stimulated cell proliferation (Figure 2c ), which could argue in favor of mitotic cell death upon DNA damages.
Because the mechanisms downstream of the VP16-induced cell death promoted by TSA versus VPA appeared distinct, these results raised the central question of how TSA and VPA yet can be as efficient in inducing sensitization to VP16-mediated cell death. We hypothesized that the sensitizing effect could depend on an increased ability of the topoisomerase II inhibitor to provoke DNA double-strand breaks. We therefore assessed DNA damage by the 'comet assay'. VP16, TSA or VPA alone produced only limited DNA damage in H157 cells as assessed by average tail moment (Figures 1c and d) . In contrast, cells co-treated with TSA/VP16 or VPA/VP16 exhibited a dramatic increase in DNA damage (Figures 1c and d) . Analysis of the phosphorylation of H2AX, one of the earliest events following the induction of double-strand breaks, confirmed these results (Figure 1e ).
TSA or VPA trigger an increase in histone H4 lysine 16 acetylation in cancer cells To investigate putative effects of the HDACi on histone acetylation, we next analyzed the steady-state level of total acetylation at specific single lysine residues on histone H3 and H4. Using specific antibodies against acetylated lysine 9 on histone H3 (H3K9), H3K14, H4K5, H4K8, H4K12 and H4K16, followed by confocal imaging analysis and immunoblotting of histone-enriched cell extracts, we detected an increased acetylation of a subset of lysine residues after treatment of H157 cells with VPA or TSA alone or in combination with VP16 (Figures 3a and b) . The most pronounced increase in acetylation was detected at H4K16 as assessed by immunocytochemistry and immunoblotting (Figures 3a-c) . H4K16 acetylation is known to influence histone-histone interactions and higher-order chromatin structure, and has previously been shown to display low levels of total acetylation in cancer cells (Fraga et al., 2005) .
To elucidate whether the effects of HDACi on H4K16 acetylation were cell specific or general in nature, we examined two additional cancer cell lines and a primary stem cell culture: NSCLC H1299 cell line, neuroblastoma SK-N-BE(2) cell line and primary fibroblast growth factor (FGF2)-expanded embryonic neural stem cells prepared from rat cortices (Jepsen et al., 2007; Andersson et al., 2009) . SK-N-BE(2) is a highly malignant cell line derived from chemotherapy-resistant neuroblastoma, which presents an intrinsic resistance to multiple drugs including several DNA-damaging agents (Keshelava et al., 1998) . Interestingly, all drug-resistant cancer cells analyzed exhibited a lower level of H4K16 acetylation compared with the drug-sensitive neural stem cells (Figure 3c ) in part consistent with previous reports (Fraga et al., 2005) . Treatment with TSA or VPA induced a clear increase in H4K16 acetylation in the cancer cells, whereas the primary neural stem cells showed high basal total H4K16 acetylation levels and this acetylation was in contrast unaffected by HDACi treatment. The level of H4K16 acetylation may thus reflect differences in chromatin acetylation machinery between stem cells and cancer cells (Figure 3c) . Interestingly, the increase in H4K16 acetylation was accompanied by the sensitization of these cancer cell lines to VP16-induced cell death (Figure 3d ), whereas the neural stem cells, displaying high basal H4K16 acetylation levels, showed massive cell death in response to VP16, without need of sensitization by HDACi. Total H4K16 acetylation levels thus correlates with the sensitivity to DNA-damaging agents in neural stem and drug-resistant cancer cells.
Overexpression of hMOF is sufficient to increase H4K16 acetylation and promote DNA damage induced cell death We next aimed at identifying the potential HAT that could mediate the effect of HDACi on acetylation of hMOF/SIRT1 control H4K16Ac and VP16 sensitivity N Hajji et al H4K16. Although many HATs show either little substrate specificity or preference for other residues, the human orthologue of the Drosophila melanogaster males absent on the first (MOF) gene, hMOF/MYST1, has been reported to acetylate histone H4 at lysine 16 (Neal et al., 2000; Smith et al., 2005; . In line with these reports, overexpression of hMOF resulted in a dramatic and selective increase in H4K16 acetylation in transfected H157 cells (Figure 4a ). We next co-transfected green fluorescent protein (GFP) with the hemagglutinin (HA)-hMOF construct or empty vector in H157 cells, followed by treatment with VP16 or vehicle for 12 h and subsequent analysis of cell death. This experiment revealed that whereas hMOF expression per se did not affect cell death, it strongly augmented the lethal effect of VP16 (Figures 4b and  c) . These experiments thus showed that overexpression of the H4K16-targeting HAT hMOF is sufficient to mimic the effects of HDACi on VP16-resistant cancer cells.
hMOF is required for HDACi-mediated increase in H4K16 acetylation and cell-death-promoting effect Although overexpression of hMOF was sufficient to mimic the effects of TSA and VPA, it remained unclear if endogenous hMOF activity had any essential role in the HDACi-mediated effects on H4K16 acetylation and DNA-damage-induced cell death. H157 cells were therefore co-transfected with GFP and either an siRNA directed against hMOF or a control siRNA. The cells were subsequently treated with VP16, TSA or both compounds. The transfection efficiency was estimated to between 40 and 60%. The control siRNA and GFP overexpression did not affect basal or TSA-increased H4K16 acetylation in H157 cells (Figure 4d ; data not hMOF/SIRT1 control H4K16Ac and VP16 sensitivity N Hajji et al shown). In contrast, there was a dramatic loss of TSAinduced increase in total H4K16 acetylation in hMOFdepleted cells compared with control cells (Figure 4d ). In addition, delivery of the siRNA-hMOF resulted in an almost complete reversal of the TSA/VP16-mediated H157 cell death without any significant influence on their survival by itself (Figures 4e and f) . These data show that endogenous hMOF activity is required for the promoting effects of HDACi on H4K16 acetylation and drug-resistant cancer cell death. 
SIRT1 inhibition mediates increase in H4K16 acetylation and promotes cell death
We next asked which HDAC could counteract the effect of hMOF by deacetylating H4K16Ac and contribute to the resistance to VP16-induced cell death. Whereas class I HDACs show little substrate specificity and the direct HDAC activity of class II HDACs has been debated, the class III HDAC SIRT1 has been reported to show preference for deacetylation of H4K16 (Vaquero et al., 2004 (Vaquero et al., , 2007 Pruitt et al., 2006) . Further, HDACs 1-8 were ubiquitously expressed in H157 cells as assessed by immunoblotting, and did not show any change in expression after VPA or TSA exposure (data not shown). VPA and TSA indeed bind directly to and inhibit class I and class II HDACs, but importantly these molecules have also been shown to affect class III sirtuin deacetylases indirectly, including SIRT1, in mammalian cells by regulating their gene expression (Kyrylenko et al., 2003; KW and OH, unpublished observations) . We therefore examined the effects of TSA and VPA exposure on SIRT1 protein levels ( Figure 5a ). In addition, we analyzed the protein levels of hMOF and SIRT2, a cytoplasmic HDAC that has been shown to deacetylate H4K16Ac during mitosis (Vaquero et al., 2006 (Vaquero et al., , 2007 . SIRT1, SIRT2 and hMOF proteins were all expressed in untreated cells. However, whereas the expression levels of both hMOF and SIRT2 remained unaltered on HDACi treatment, both TSA and VPA stimulation led to a significant decrease in SIRT1 protein levels within 3 h (Figure 5a ).
H157 cells were next co-transfected with DsRedMito and either an siRNA directed against human SIRT1 or a control siRNA, followed by subsequent treatment with VP16. Confocal imaging revealed a clear increase in H4K16 acetylation in SIRT1-depleted H157 cells compared to neighboring nontransfected cells (Figure 5b ). H157 cells co-transfected with GFP/SIRT1 siRNA or GFP/control siRNA were then treated with VP16 or vehicle for 12 h and the cell death was assessed (Figure 5c ). In contrast to hMOF overexpression, incubation of H157 cells with siRNA directed against SIRT1 was sufficient to reduce their survival, indicating that SIRT1 may have multiple roles in cell death and survival as previously reported (Figure 5c ; Deng, 2009; Liu et al., 2009) . Importantly however, SIRT1 silencing resulted in a significant increase in VP16-induced cell death. Similar results regarding sensitization and H4K16 acetylation were obtained using EX-527, a selective inhibitor of SIRT1 that does not inhibit HDAC or other sirtuin deacetylase family members (Napper et al., 2005; Figures 5d and e) . These data indicate that inhibition of SIRT1 activity resulted in the sensitization to cell death induced by topoisomerase II inhibitor, and that this effect was associated with an increase in total H4K16 acetylation.
SIRT1 downregulation is required for TSA-mediated increase in H4K16 acetylation and death-promoting effect We next assessed whether SIRT1 downregulation was required for the HDACi promotion of cancer cell death. We therefore transiently overexpressed Flag-tagged SIRT1 in H157 cells and treated them with TSA for 3 h. Overexpression of SIRT1 in H157 cells resulted in an abolishment of the TSA-induced increase in H4K16 acetylation as assessed by single-cell analysis (Figure 5f ). We next co-transfected GFP with the Flag-SIRT1 construct or empty vector in H157 cells, followed by treatment with vehicle, TSA, VP16 or the combined treatment TSA/VP16 for 12 h and assessed the cell death. This experiment revealed that whereas SIRT1 overexpression by itself did not affect the rate of cell death, it drastically decreased the killing effect of TSA/ VP16 (Figures 5g and h) . These experiments thus suggest that overexpression of SIRT1 is sufficient to inhibit the sensitizing effects of TSA on drug-resistant NSCLC cells.
Opposing effects of hMOF and SIRT1 regulate the response of cancer cells to topoisomerase II inhibition On the basis of these results, we hypothesized that a direct balance between the opposing effects of hMOF and SIRT1 may control the responsiveness of cancer cells to the topoisomerase II inhibitor VP16. To test this hypothesis, we co-transfected H157 cells with different ratios of SIRT1 and hMOF (1:0; 1:0.5; 1:1; 1:1.5 and 1:2), treated with VP16 for 24 h and subsequently examined for cell death (Figure 6a ). Intriguingly, transfecting increasing levels of SIRT1 inhibited the stimulation by hMOF on VP16-induced cell death in a dose-dependent manner, whereas increasing levels of hMOF expression conversely inhibited the survival effect of SIRT1 expression after exposure to the topoisomerase II inhibitor.
Discussion
A number of studies have previously shown that treatment with diverse HDACi triggers or promotes cell death in different types of cancer cells, resulting in a 
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Figure 4 Human males absent on the first (hMOF) provokes lysine 16 on histone H4 (H4K16) acetylation and sensitizes H157 cells to VP16-induced cell death. (a) H157 cells were transfected with a plasmid encoding HA-tagged hMOF or the corresponding empty vector. Cells were fixed and immunofluorescence detection was performed using antibodies directed against the HA tag and H4K16Ac. Nuclei were counterstained with 4 0 ,6-diamidino-2-phenylindole (DAPI). Confocal images of immunostaining with HA-hMOF (red), H4K16Ac (green) antibodies and nuclear DAPI staining (blue) of H157 cells on hMOF overexpression are depicted. (b, c) H157 cells were co-transfected with a plasmid encoding HA-tagged hMOF or the corresponding empty vector and green fluorescent protein (GFP) and then treated with VP16 (5 mM) for 24 h (b). Cells were fixed and immunofluorescence detection was performed using antibodies directed against the HA tag of hMOF. Nuclei were counterstained with DAPI. Confocal images of GFP (green), immunostaining with HA-hMOF antibodies (red) and nuclear DAPI staining (blue) of H157 cells on hMOF overexpression and treatment are depicted. (c) Cell death was assayed as described in Figure 1 . A total of 300 nuclei from GFP-expressing cells were analyzed in duplicate and each experiment was repeated three times. Data are represented as mean ± s.e.m. (d-f) H157 cells were transiently co-transfected with plasmid encoding GFP together with small-interfering RNAs (siRNAs) pool designed to interfere specifically with the expression of human MOF. As control, an siRNA directed against enhanced cyan fluorescent protein (ECFP) was used. At 24 h after transfection, cells were treated with VP16, trichostatin A (TSA) or a combination of both, and incubated for additional 24 h. (d) Confocal analysis of H4K16 acetylation performed by immunofluorescence using a polyclonal antibody against H4K16Ac revealed by an Alexa Fluor 594-conjugated secondary antibody. Nuclei were counterstained with DAPI. GFP was used as transfection maker. Confocal images of GFP (green), immunostaining with H4K16Ac (red) antibodies and nuclear DAPI staining (blue) of H157 cells after TSA treatment are depicted. (e) Confocal images of GFP (green), nuclear DAPI staining (blue) of H157 cells after TSA/VP16 treatment are depicted. Asterisks in panel indicate condensed/fragmented cell nuclei. These experiments were performed three times with similar results. (f) Cell death was assayed by scoring of GFP-expressing cells presenting condensed/ fragmented nuclei. A total of 300 nuclei were analyzed in duplicate and each experiment was repeated three times. Bars and error bars represent mean with s.e.m. hMOF/SIRT1 control H4K16Ac and VP16 sensitivity N Hajji et al remained unclear. Our study results reveal a novel and unexpected mechanism underlying HDACi-induced effects on multidrug-resistant cells to topoisomerase II inhibitor involving hMOF and SIRT1. We speculate that the effects could depend on the opposing activities of hMOF and SIRT1 on H4K16 acetylation and thus increased chromatin accessibility (Shogren-Knaak et al., 2006; Figure 6b ). Importantly, this single histone modification influences both higher-order chromatin structure and functional interactions between histones as well as a non-histone protein and the chromatin fiber (ShogrenKnaak et al., 2006) . It has been shown that reduction in H4K16 acetylation correlate with tumor progression (Fraga et al., 2005) . In addition, the enzymatic components of the regulatory system described in this study have been reported to be altered in cancer disease, although it should noted that both hMOF and SIRT1 have been associated with both survival and deathpromoting mechanisms. For example, hMOF expression is frequently downregulated in primary breast carcinoma and medulloblastoma and constitutes a biomarker for clinical outcome in medulloblastoma (Pfister et al., 2008) . There is however additional evidence that hMOF, similar to the related HAT Tip60, is involved in mechanisms leading to DNA repair as well as in death signaling pathways (Ikura et al., 2000) . The cell fate may depend on the amount of DNA damage, exemplified by the fact that Tip60 appears to exert its effect primarily at the initial phase of DNA damage (Ikura et al., 2000) .
The function of SIRT1 in different cell contexts seems to be even more complex. SIRT1 expression is significantly elevated in prostate and colon cancers (Huffman et al., 2007; Stunkel et al., 2007) , and HIC1 (hypermethylated in cancer 1), an inhibitor of SIRT1 transcription, is epigenetically silenced in many tumors (Chen et al., 2005) . SIRT1 has however in addition to H4K16 been shown to be a protein deacetylase, and plural effects of SIRT1 on cell survival have been reported. SIRT1 has been shown to promote cell survival by deacetylating the DNA-damage-protecting protein NBS1 (Yuan et al., 2007) . SIRT1 has also been shown to regulate acetylation levels of p53, but the implications of this regulation are less clear as it has been reported on one hand that SIRT1 deacetylation influences p53-dependent DNA damage response, but on the other that the SIRT1-mediated p53 acetylation has a minor biological role (Vaziri et al., 2001; Motta et al., 2004) . It is therefore worth noting that none of the cancer cell lines used in this study expresses functional p53. Furthermore, SIRT1 does not exert protective effect after DNA damage in all cell types (Solomon et al., 2006) , and cytoplasm-localized SIRT1 has even been reported to enhance apoptosis (Jin et al., 2007) . Thus the subcellular localization, expression and activity levels of SIRT1 are essential for its effect on cell survival (Deng, 2009; Liu et al., 2009) .
Altogether, our observations support a model where the hMOF/SIRT1 enzymatic system regulates H4K16 acetylation levels and where its deregulation is associated with cancer occurrence and sensitivity to topoisomerase inhibitor (Figure 6b) . The results of our study may further provide a mechanism justifying ongoing clinical trials on neuroectodermal tumors using combined treatment with valproate and etoposide (www. clinicaltrials.gov).
Materials and methods

Reagents
Etoposide (Vepeside, VP16, 20 mg/ml in dextran) was from Bristol-Myers (New York, NY, USA). 6-Chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide (EX-527; 50 mm in ethanol; Tocris Bioscience, Ellisville, MO, USA), TSA (1 mm in dimethyl sulfoxide; Sigma) and 2-propylpentanoic acid (VPA, 1 M in ethanol; Sigma) were stored at À20 1C in dark. Subsequent dilutions were performed in culture medium.
Cell culture and treatments
Human non-small-cell lung carcinoma cell line NCL-H157 (CRL-5802; ATCC, Manassas, VA, USA) and NCI-H1299 (CRL-5803; ATCC) and human neuroblastoma SK-N-BE(2) cell line (CRL-2271; ATCC) were used in this study (Joseph et al., 2001 (Joseph et al., , 2002 . None of the cell lines express functional p53: one is p53 null, one has a frameshift in p53 and the third has a p53 hot stop mutation (p53 mutation databases at http:// www-p53.iarc.fr and http://p53.free.fr). Cells were cultured at 37 1C, 5% CO 2 in RPMI 1640 medium (H157 and H1299), or modified Eagle's medium mixed with F-12 Nutrient Mixture (Ham) at ratio 1:1 (SK-N-BE (2)), all supplemented with 10% heat-inactivated fetal calf serum, 2 mm l-glutamine, penicillin (100 U/ml) and streptomycin (100 mg/ml).
Isolation and culture of multipotent neural progenitors, referred to as neural stem cells, were performed essentially as described elsewhere (Jepsen et al., 2007; Andersson et al., 2009) . In brief, cortices from rats at embryonic day 15 were dissected and mechanically dispersed in a modified serum-free, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)-free N2-supplemented Dulbecco's modified Eagle's medium/ F12 medium. The primary cells were plated on 35 mm dishes coated with poly-l-ornithine and fibronectin (Sigma). The cells were treated with human recombinant basic FGF2 at 10 ng/ml every 24 h and the N2 medium was replaced every 48 h. All treatments were performed after the first passage when 499% of the cells showed nestin expression and typical neural stem cell morphology and o1% of the cells expressed neuronal and glial differentiation markers.
At 24 h after setting in culture dishes with fresh medium, we treated cells with 5 mm VP16, 1 mm VPA, 20 ng/ml TSA alone or in combination. The cell density was kept at levels allowing exponential growth.
Detection of cell death
After treatment, cells were fixed in 4% paraformaldehyde and subsequently DNA was stained with Hoechst 33342 (0.1 mg/ml; Molecular Probes, Paisley, UK). The number of dying cells was measured quantitatively by assessing the percentage of cells with fragmented, damaged or condensed nuclei.
Colony formation assay
Cell survival after treatment was measured by clonogenic assay in monolayer (Gallego et al., 2004) . Single-cell suspensions were plated out at 500 cells per 100 mm dish in triplicate. Cells were hMOF/SIRT1 control H4K16Ac and VP16 sensitivity N Hajji et al then exposed for 24 h to the HDACi alone or in combination with VP16. After washes, cells were incubated in complete culture medium at 37 1C for an additional 10-day period. Eventually, the medium was aspirated and dishes were fixed in methanol and stained with 3% Giemsa for 30 min, then rinsed and air-dried. Surviving colonies made up of more than 50 cells per colony were counted. The size of the individual colonies after treatment was measured with ImageJ software (US National Institutes of Health, Bethesda, MD, USA). The survival data were normalized to the cloning efficiencies of untreated controls. Three separate experiments were carried out for each treatment.
Extraction of acid-soluble nuclear proteins, western blot To detect single acetylated lysine residue on histone H4 and H3 tails, we extracted acid-soluble nuclear proteins as follows: cells were spun down, washed with phosphate-buffered saline, and resuspended in an histone lysis buffer containing 10 mM Tris (pH 6.5), 50 mM sodium bisulfate, 10 mM MgCl 2 , 8.6% sucrose, 1% Triton X-100 and 0.2 M sulfuric acid, and incubated on ice for 1 h. Samples were then centrifuged at 11 000 g for 30 min at 4 1C and the supernatant were precipitated with acetone overnight, and centrifuged at 11 000 g for 1 h at 4 1C. Pellets were dried out at room temperature. Acid-extracted histones were obtained by centrifugation at 11 000 g for 1 h at 4 1C, and the concentrations of histones were measured by the Bradford method. After separation by SDS-polyacrylamide gel electrophoresis (15% gel), proteins were transferred on to nitrocellulose membrane (Amersham, Uppsala, Sweden). Membranes were blocked for 2 h with 5% non-fat milk in phosphate-buffered saline at room temperature and subsequently probed overnight with primary Figure S1 ).
Immunofluorescence and confocal microscopy
For confocal microscope analysis, the adherent cells were grown on coverslips. Anti-HA (Roche, Indianapolis, IN, USA), phosphorylated g-H2AX (Upstate Biotechnology) and acetylated H3K9, H3K14, H4K5, H4K8, H4K12, H4K16 (Upstate Biotechnology) antibodies were used in immunodetection. Alexa Fluor 488-or 594-conjugated anti-IgGs were used as secondary antibodies (Molecular Probes). Paraformaldehyde-fixed cells were blocked in HEPES/3% bovine serum albumin/0.3% Triton X-100 and incubated with primary (4 1C, overnight) and secondary antibodies (room temperature, 1 h).
Cell nuclei were counterstained with 4 0 ,6-diamidino-2-phenylindole (DAPI; 1 mg/ml). Samples were mounted with Vectashield (Vector Laboratories, Burlingame, CA, USA) and analyzed with Zeiss 510 META confocal laser scanning microscopy (Zeiss, Jena, Germany) equipped with an inverted Zeiss Axiovert 200 microscope with an a Â 63 oil immersion objective. Mix dyes were acquired by sequential multiple channel fluorescence scanning to avoid bleeds through. Routinely, 0.15-0.20 mM thick focal planes were scanned. Chats were quantified and images were processed using the Zeiss software (LSM 510 Meta).
Immunoblotting analysis
Total protein extracts were carried out as reported (Nyman et al., 2009) . For immunoblot analysis, protein extracts were resolved on SDS-polyacrylamide gel electrophoresis and blotted; protein pieces were detected with antibodies raised against SIRT1, SIRT2 (both from Cell Signaling, Beverely, MA, USA), and hMOF (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Immunoblot with anti-G3PDH (Trevigen, Gaithersburg, MD, USA) was used for standardization of protein loading.
Comet assay
Comet assay essentially measures the degree of fragmentation of DNA within the cell. The comet assay was performed as described previously (Singh et al., 1988) . Briefly, 10 000 cells were mixed with 85 ml low-melting agarose (0.7% in phosphate-buffered saline) kept at 37 1C and the cell-agarose mixture was placed on 1% normal-melting agarose-coated glass slides and covered with a coverslip. The cell-agarose mixtures were allowed to solidify for 10 min at 4 1C. The coverslip was removed and further 100 ml low-melting agarose was added. After solidification at 4 1C, the samples were incubated for 60 min in a chilled lysis buffer containing 2.5 M NaCl, 100 mM Na 2 EDTA, 10 mM Tris, 1% sodium sarcosinate, 1% Triton X-100, and 10% dimethyl sulfoxide (pH 10). Subsequently, the slides were drained and placed in a horizontal gel electrophoresis unit. The chamber was filled with chilled electrophoresis buffer for alkaline comet assay (1 mM Na 2 EDTA, 300 mM NaOH (pH 12.8)) and the samples were left in this solution for 20 min to allow unwinding of the 0 ,6-diamidino-2-phenylindole (DAPI). DsRed-Mito was used as transfection maker. Confocal images of DsRed-Mito (red), immunostaining with H4K16Ac (green) antibodies and nuclear DAPI staining (blue) of H157 cells after TSA treatment are depicted. (c) At 24 h after transfection, cells were treated with VP16, and incubated for additional 12 h. Cell death was assayed by scoring of GFP-expressing cells presenting condensed/fragmented nuclei. A total of 300 nuclei were analyzed in duplicate and each experiment was repeated three times. Bars and error bars represent mean with s.e.m. (d) H157 cells were treated with EX-527 (1 mm) for 3 h. Cells were fixed and immunofluorescence detection was performed using antibodies directed against H4K16Ac. Nuclei were counterstained with DAPI. (e) H157 cells were treated with EX-527 (1 mm) alone or in combination with VP16 (5 mm) for 24 h. Cell death was assayed as in Figure 1 . (f) H157 cells were transfected with a plasmid encoding Flag-tagged SIRT1 or the corresponding empty vector. At 24 h after transfection, cells were treated with TSA, and incubated for additional 3 h. Cells were fixed and immunofluorescence detection was performed using antibodies directed against H4K16Ac. Nuclei were counterstained with DAPI. Confocal images of immunostaining with Flag (red), H4K16Ac (green) antibodies and nuclear DAPI staining (blue) of H157 cells on SIRT1 overexpression are depicted. (g, h) H157 cells were transiently co-transfected with plasmid encoding GFP together with Flag-tagged SIRT1 or the corresponding empty vector. At 24 h after transfection, cells were treated with VP16, TSA or a combination of both, and incubated for additional 12 h. (g) Confocal images of GFP (green), nuclear DAPI staining (blue) of H157 cells after TSA/VP16 treatment are depicted. Asterisks in the panel indicate condensed/fragmented cell nuclei. These experiments were performed three times with similar results. (h) Cell death was assayed by scoring of GFP-expressing cells presenting condensed/fragmented nuclei. A total of 300 nuclei were analyzed in duplicate and each experiment was repeated three times. Bars and error bars represent mean with s.e.m.
hMOF/SIRT1 control H4K16Ac and VP16 sensitivity N Hajji et al DNA. Electrophoresis was then performed (25 V, 300 mA, 4 1C, 20 min). After electrophoresis, slides were washed in a neutralization buffer 400 mM Tris (pH 7.5) to remove alkali and detergent, and stained with DAPI (5 mg/ml) in Vectashield. DNA of individual cells was viewed using an epifluorescence microscope Olympus Vanox AHBT3 (Tokyo, Japan), with an excitation filter of 550 nm and barrier filter of 590 nm, connected to a CCD camera. The quantitative analysis was performed with the specially designed software CometScore (Sumerduck, VA, USA). Pseudocolor of isolated nuclei was attributed by the AutoComet program and reflects the condensation state of the chromatin. DNA single-strand breaks were measured using the tail moment parameter, the product of the percentage of DNA in the comet tail and the mean tail length.
Statistical analysis
Statistical analyses were performed using two-tailed, paired Student's t-test, and one-way analysis of variance, where **P-valueo0.01 and *P-valueo0.05.
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